BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Tumor-Associated Microbiome: Where Do We Stand? Int J Mol Sci 2021;22:1446. [PMID: 33535583 DOI: 10.3390/ijms22031446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Stella GM, Scialò F, Bortolotto C, Agustoni F, Sanci V, Saddi J, Casali L, Corsico AG, Bianco A. Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review. Cancers 2022;14:3131. [DOI: 10.3390/cancers14133131] [Reference Citation Analysis]
2 Smorodin EP. Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer. Int J Mol Sci 2021;22:11608. [PMID: 34769037 DOI: 10.3390/ijms222111608] [Reference Citation Analysis]
3 Chen J, Li T, Liang J, Huang Q, Huang JD, Ke Y, Sun H. Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy. Biomed Pharmacother 2022;145:112443. [PMID: 34847476 DOI: 10.1016/j.biopha.2021.112443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Too NSH, Ho NCW, Adine C, Iyer NG, Fong ELS. Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models. Adv Drug Deliv Rev 2021;175:113791. [PMID: 33965462 DOI: 10.1016/j.addr.2021.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chen Y, Wu F, Wu P, Xing H, Ma T. The Role of The Tumor Microbiome in Tumor Development and Its Treatment. Front Immunol 2022;13:935846. [DOI: 10.3389/fimmu.2022.935846] [Reference Citation Analysis]
6 Bhat SA, Kaur R, Chauhan A, Pal A. The microbiome and precision oncology: an emerging paradigm in anticancer therapy. Crit Rev Microbiol 2022;:1-14. [PMID: 35164642 DOI: 10.1080/1040841X.2022.2035313] [Reference Citation Analysis]
7 Chen Y, Lai X. Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer. Math Biosci 2022;:108868. [PMID: 35753521 DOI: 10.1016/j.mbs.2022.108868] [Reference Citation Analysis]
8 Sharma R, Kannourakis G, Prithviraj P, Ahmed N. Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. Front Med 2022;9:766869. [DOI: 10.3389/fmed.2022.766869] [Reference Citation Analysis]
9 Chu CS, Yang CY, Yeh CC, Lin RT, Chen CC, Bai LY, Hung MC, Lin CC, Wu CY, Lin JT. Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study. Sci Rep 2022;12:107. [PMID: 34997106 DOI: 10.1038/s41598-021-04095-w] [Reference Citation Analysis]
10 Flores de los Rios PA, Casañas Pimentel RG, San Martín Martínez E. Nanodrugs against cancer: biological considerations in its redesign. International Journal of Polymeric Materials and Polymeric Biomaterials. [DOI: 10.1080/00914037.2022.2097680] [Reference Citation Analysis]
11 Zhou X, Kandalai S, Hossain F, Zheng Q. Tumor microbiome metabolism: A game changer in cancer development and therapy. Front Oncol 2022;12:933407. [DOI: 10.3389/fonc.2022.933407] [Reference Citation Analysis]